ATX-304 (O304): what preclinical work shows about pan-AMPK activation

ATX-304 is a synthetic small molecule, not a peptide. It appears here because it is often discussed alongside mitochondrial-derived peptides such as MOTS-c: both are used as tools to study AMPK, the cell’s central energy sensor.

AMPK is a heterotrimeric kinase (α, β and γ subunits) that is switched on when the AMP:ATP ratio rises. Once active, it shifts cells away from energy-consuming synthesis and toward fuel uptake and oxidation. Many AMPK activators studied to date act on only some subunit combinations. O304 was described as a “pan-AMPK” activator that suppresses dephosphorylation of the activating site (Thr172) across isoforms.

In the founding report (Steneberg et al., JCI Insight, 2018), investigators measured glucose tolerance, insulin sensitivity, skeletal-muscle glucose uptake and microvascular perfusion in a high-fat-diet mouse model, and reported changes in each consistent with AMPK activation in muscle. They compared the profile with the AMPK activation that exercise produces.

Later work from the same group examined β-cell stress markers and cardiac energetics in rodent models, including aged mice. These are single-group findings and still need independent confirmation.

Chronic, system-wide AMPK activation is not obviously benign. AMPK interacts with mTOR signaling, autophagy and cardiac hypertrophy pathways, and some activating mutations in the γ2 subunit cause cardiac glycogen storage disease. How ATX-304’s isoform profile avoids or reproduces these effects is an active question.

Independent replication across laboratories, strains and diets would strengthen the existing data. So would direct comparisons with other AMPK activators such as AICAR, A-769662 and MK-8722.